Acute Kidney Injury Treatment

Acute Kidney Injury Treatment Market Size (2024 to 2032):

The size of the global acute kidney injury treatment market was worth USD 5.81 billion in 2023. The global market is anticipated to grow at a CAGR of 5.03% from 2024 to 2032 and be worth USD 9.04 billion by 2032 from USD 6.10 billion in 2024. 

MARKET DRIVERS

The growing incidence of acute kidney injuries is one of the major factors propelling the growth of the acute kidney injury treatment market. According to the International Society of Nephrology, around 14.5 million cases of acute kidney injury worldwide each year and 1.8 million deaths are recorded globally. The growing patient population suffering from acute kidney injuries demands for efficient treatment for disease and driving the market growth.

The growing number of research and development activities for treating acute kidney injury fuels the growth rate of the acute kidney injury treatment market. Developing novel therapeutics and AKI treatment alternatives is made possible through R&D initiatives. To evaluate the efficacy and effectiveness of innovative therapeutics, scientists and pharmaceutical companies devote resources to researching the fundamental causes of AKI to identify possible pharmacological targets and carry out preclinical and clinical trials. By giving patients and healthcare professionals more alternatives, developing novel and cutting-edge treatments can accelerate the growth potential for AKI treatments. R&D efforts are concentrated on enhancing diagnostic methods and instruments for the timely and precise diagnosis of AKI. To improve AKI diagnosis and monitoring, cutting-edge biomarkers, imaging techniques, and point-of-care testing approaches are being investigated. These advancements may result in more accurate and effective diagnoses, allowing for prompt treatment and improved patient results.

The growing geriatric population worldwide propels the growth of the AKI treatment market due to age-associated physiological changes, numerous comorbidities, and the use of drugs that may impact renal function. Older people have a higher risk of developing AKI. The prevalence of AKI among the geriatric population is growing rapidly worldwide, fuelling the need for AKI treatment. Chronic diseases such as diabetes, hypertension, and cardiovascular illnesses are known risk factors for AKI and are frequently more prevalent as people age. AKI is more likely to affect the older population who have certain underlying chronic illnesses, demanding the need for effective treatment as well as management techniques. Renal replacement therapies (RRT), such as hemodialysis or peritoneal dialysis, may be necessary for severe AKI. The need for RRT is increasing as the number of elderly people increases because of AKI. To give senior AKI patients the appropriate care, more dialysis services and associated technology are required.

Factors such as advancements in diagnostic technologies, rising awareness and education among individuals regarding AKI and available treatment options and an increasing number of initiatives and policies from the governments of several countries in favor of AKI treatment further propel the AKI treatment market growth.

MARKET RESTRAINTS

The high costs associated with acute kidney injury treatment and the lack of awareness among people majorly hinder the global market growth. AKI might not be as well-known to the public as various chronic kidney disorders, which would make people less aware of it. Many people could overlook the early indications of AKI, put off getting treatment, or downplay how serious the situation is. Due to a lack of information, treatment results may be delayed or ineffectively managed. The expense of treating AKI can be high, particularly when the patient needs acute care, renal replacement therapy (RRT), or hospitalization. Individuals, medical facilities, and insurance may be financially burdened by the costs of hospital stays, drugs, dialysis, and specialized therapies. Access to the best care may be restricted and the use of cutting-edge treatment alternatives may be hampered by high treatment expenses and impede the global market growth.

Impact of COVID-19 on the Acute Kidney Injury Treatment Market:

The coronavirus can directly affect the kidneys and can result in acute kidney injury in some patients. Patients who are severely ill with COVID-19 may develop AKI because of causes such as organ malfunction, infection and systemic inflammation. The need for AKI treatments and management techniques has increased during the COVID-19 pandemic due to the rise in AKI patients linked to COVID-19. The growing number of COVID-19 cases has burdened healthcare resources such as staff, beds and equipment. This burden has made it difficult to give AKI patients the best care possible, potentially causing delays in AKI evaluation, therapy and management. The lack of funding for COVID-19 treatment has also impacted the affordability and accessibility of AKI treatment alternatives. The COVID-19 pandemic has caused numerous clinical trials and research projects looking at AKI treatment to be postponed or interrupted. The advancements of ongoing investigations and the creation of fresh treatments for AKI have been hampered by constraints on investigations, resource redistribution, and prioritization of COVID-19-related research. The COVID-19 pandemic crisis has had a detrimental effect on the acute kidney injury treatment market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Acute Kidney Injury Treatment Market Analysis By Type

• Prerenal
• Intrinsic Renal
• Post Renal

Based on type, the prerenal acute kidney injury segment is expected to continue to dominate the market during the forecast period owing to the growing patient population suffering from acute kidney injury.

The intrinsic renal acute kidney injury segment is estimated to hold a considerable share of the global market during the forecast period. Factors such as the growing aging population, rising prevalence of chronic kidney illnesses, consumption of nephrotoxic medicines and growing instances of sepsis- or ischemia-related kidney damage primarily contribute to the rising prevalence of intrinsic renal AKI. The need for efficient treatment alternatives is being driven in part by the increasing prevalence of intrinsic renal AKI.

Global Acute Kidney Injury Treatment Market Analysis By Treatment

• Therapy
• Drugs

Based on treatment, the drugs segment is expected to hold the major share of the global market during the forecast period owing to the presence of drugs such as recombinant alkaline phosphate and nephrotoxic agents. Also, the key companies in the market focused more on strategies such as raising funds for the treatment of acute kidney injury.

The therapy segment is anticipated to register a healthy CAGR during the forecast period. For AKI patients with significant kidney impairment, renal replacement therapies such as hemodialysis and peritoneal dialysis are important therapy options. Technological developments in RRT methods, such as enhanced dialyzers, equipment, and solutions, support the expansion of the therapy segment in the global market. These developments boost RRT's effectiveness, safety, and convenience for patients, propelling segmental growth.

Global Acute Kidney Injury Treatment Market Analysis By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on the distribution channel, the online pharmacies segment is expected to gain momentum and account for a substantial share of the worldwide market during the forecast period. The COVID-19 pandemic situation has fuelled the adoption of digital commerce platforms, including online pharmacies. The trend is anticipated to continue in the coming years and drive the segmental growth further.

The hospital pharmacies segment is estimated to capture a noteworthy share of the global market during the forecast period owing to the rising patient population suffering from acute kidney injuries, increasing number of patient visits to the hospitals for the treatment needs and rising awareness among people regarding the disease.

REGIONAL ANALYSIS

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Based on region, the North American region is expected to occupy the largest share of the worldwide market during the forecast period. The U.S. is rapidly developing improved and mechanized AKI diagnostic technology as awareness of the treatment for acute renal illness rises. To improve patient care, many private healthcare organizations are adopting more advanced AKI technology. Several key market participants have been investing considerable amounts in the development of advanced products to treat AKI in the U.S. and capture the U.S. market potential.

The AKI market in the Asia-Pacific region is expected to witness the highest CAGR among all the regions in the worldwide market during the forecast period. With the opening of these facilities, healthcare practitioners are using AKI treatment equipment more frequently. Rapid technical developments in medical facilities and supportive governmental regulations are facilitating the use of cutting-edge AKI technology and diagnostic procedures, which favors the APAC market growth. The sales of AKI treatment diagnostic equipment in these dialysis facilities are anticipated to increase as acute renal disease therapy becomes more widely known. Increased financial resources and increased health awareness have made it possible for patients to choose modern therapy for various ailments, and major companies are focusing on developing and launching revolutionary products in India.

Europe is predicted to account for a considerable share of the global market during the forecast period. Factors such as the presence of a strong healthcare infrastructure, encouraging R&D, favorable government policies into action, addressing the requirements of the aging population, and encouraging collaboration and guideline-based treatment drive the growth of the European market.

Latin America is expected to register a steady CAGR during the forecast period. The growing awareness and access to healthcare, increasing number of programs from the governments of Latin American countries and growing number of collaborations between the key market participants in the field of AKI therapy drive the growth of the Latin American market.

The Middle East and Africa region is expected to grow at a moderate CAGR in the coming years.

KEY MARKET PLAYERS

Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp and Mylan Pharmaceutical ltd. are some of the major companies in the global AKI treatment market.

RECENT MARKET DEVELOPMENTS

• In March 2021, C-Path announced the launch of an acute kidney injury project in partnership with the USA Food and Drug Administration (FDA) for Drug Evaluation and Research, the Office of Translational Science, and the Division of Cardiology and Nephrology to develop a suite of prognostic tools to improve the detection of drug-induced kidney injury.
• In June 2021, Abionyxx announced the enrollment of the first patient in its Phase-2a clinical study with CER-001 for the treatment of septic patients at high risk of developing acute kidney injury.